VolitionRx Ltd. is preparing a reimbursement submission for its Nu.Q Cancer assays to government agencies in France, a development that could significantly impact lung cancer management in the country. The submission will be actively supported by Hospices Civils de Lyon, France's second-largest university hospital system, and will run in parallel with the previously announced clinical certification process at HCL.
Researchers at HCL indicated that the Nu.Q Cancer test is intended to be introduced into routine, reimbursed clinical practice for lung cancer management in France following completion of the reimbursement and certification processes. Data generated through collaboration with Volition shows that measuring methylated nucleosome biomarkers at the time of non-small cell lung cancer diagnosis can provide information related to survival and disease progression. This approach may also help identify patients who could benefit from curative care.
The reimbursement submission is expected to be filed under France's "Innovative Procedures Outside the Nomenclature" framework, which allows early reimbursement support for innovative medical procedures. Volition noted that reimbursement would represent a major milestone toward routine clinical use of Nu.Q Cancer assays in France and support broader commercialization and potential licensing discussions in other markets.
This development is important because it represents a significant step toward making advanced cancer detection technology more accessible to patients in France. The Nu.Q Cancer assays could provide clinicians with valuable information about patient prognosis and treatment options, potentially improving outcomes for those diagnosed with lung cancer. The collaboration with Hospices Civils de Lyon lends credibility to the technology and suggests confidence in its clinical utility.
The potential impact extends beyond France, as successful reimbursement and certification in one European market could pave the way for adoption in other countries. For patients, this technology could mean earlier detection of disease progression and more personalized treatment approaches. For the healthcare system, it represents an opportunity to implement more precise cancer management strategies that could improve patient outcomes while potentially optimizing resource allocation.
Volition is a multi-national epigenetics company focused on advancing the science of epigenetics and developing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For more information about the company, visit https://www.Volition.com.
